|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Adenotonsillectomy for treatment of obstructive sleep apnea in ehildren 显示文摘 | Suen JS Arnold JE Brooks LJ | 1995 | Arch Otolaryngol Head Neck Surg1995，121，5： | 1 |
| 2 | Adenotonsillectomy for treatment of obstructive sleep apnea in children显示文摘 | Suen JS Arnold JE Brooks LI | 1995 | Arch Otolaryngol Head Neck Surg1995，121，5： | 1 |
| 3 | Adenotonsillectomy for treatment of obstructive sleep apnea in children显示文摘 | Suen JS Arnold JE Brooks LJ | 1995 | Arch Otolaryngol Head Neck Surg1995，121，： | 1 |
| 4 | Adenotonsillectomy for treatment of obstructive sleep apnea in children显示文摘 | Suen JS Arnold JE Brooks LJ | 1995 | Arch Otolaryngol Head Neck Surg1995，121，： | 1 |
| 5 | Adenotonsillectomy for treatment of obstructive sleep apnea in children显示文摘 | Suen JS Arnold JE Brooks LJ | 1995 | Arch Otolaryngol Head Neck Surg1995，121，： | 1 |
| 6 | Adenotonsillectomy for treatment of obstructive sleep apnea in children显示文摘 | Suen JS Arnold JE Brook LJ | 1995 | Arch Otolarygol Neck Surg1995，121，5： | 1 |
| 7 | Adenotonsillectomy for treatment of obstructive sleep apnea in children 显示文摘 | Suen JS Arnold JE Brooks LJ | 1995 | Arch Otolaryngol Head Neck Surg1995，121，5： | 1 |
| 8 | Adenotonsillectomy for treatment of obstructive sleep apnea in children 显示文摘 | Suen JS Arnold JE Brooks LJ | 1995 | Arch Otolaryngol Head Neek Surg1995，121，： | 1 |
| 9 | Adenotonsillectomy for treatment of obstructive sleep apnea in children 显示文摘 | Suen JS Arnold JE Brooks LJ | 1995 | Arch Otorlaryngol Head Neck Surg1995，121，5： | 1 |
| 10 | The malignancy-sarcoidosis syndrome显示文摘 | Suen JS Forse MS Hyland RH | 1990 | Chest1990，98，5： | 1 |
| 11 | Ingestion of ferrous sulfate increases ferremia in patients with short bowel syndrome 显示文摘 | Gabriel FR Suen VM Marchini JS | 2009 | Nutrition2009，25，1112： | 1 |
| 12 | Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies显示文摘Objective:Chemotherapy-induced nausea and vomiting(CINV)are common with doxorubicin-cyclophosphamide(AC)chemotherapy.Recommended antiemetic regimens incorporate neurokinin-1 receptor antagonist(NK1 RA),5-hydroxytryptamine type-3 receptor antagonist(5 HT3 RA),corticosteroid,and dopamine antagonists.This post-hoc analysis compared results of 3 prospective antiemetic studies conducted among Chinese breast cancer patients who received(neo)adjuvant AC,in order to identify optimal antiemetic prophylaxis.Methods:A total of 304 patients were included:Group 1,ondansetron/dexamethasone(D1);Group 2,aprepitant/ondansetron/dexamethasone(D1);Group 3,aprepitant/ondansetron/dexamethasone(D1–3);Group 4,aprepitant/ondansetron/dexamethasone(D1–3)/olanzapine;and Group 5,netupitant/palonosetron/dexamethasone(D1–3).Antiemetic efficacies of Groups 3,4,and 5 during cycle 1 of AC were individually compared with Group 1.In addition,emesis outcomes of patients in Groups 3 and 5,and those of Groups 2 and 3,were compared.Results:When comparing efficacies of a historical doublet(5 HT3 RA/dexamethasone)with triplet antiemetic regimens(NK1 RA/5 HT3 RA/dexamethasone)with/without olanzapine,complete response(CR)percentages and quality of life(QOL)in overall phase of cycle 1 AC were compared between Group 1 and the other groups:Group 1 vs.3,41.9%vs.38.3%(P=0.6849);Group 1 vs.4,41.9%vs.65.0%(P=0.0107);and Group 1 vs.5,41.9%vs.60.0%(P=0.0460).Groups 4 and 5 achieved a better QOL.When comparing netupitant-based(Group 3)with aprepitant-based(Group 5)triplet antiemetics,CR percentages were 38.3%vs.60.0%,respectively(P=0.0176);Group 5 achieved a better QOL.When comparing 1 day(Group 2)vs.3 day(Group 3)dexamethasone,CR percentages were 46.8%and 38.3%,respectively(P=0.3459);Group 3 had a worse QOL.Conclusions:Aprepitant-containing triplets were non-superior to doublet antiemetics.Netupitant-containing triplets and adding olanzapine to aprepitant-containing triplets were superior to doublets.Netupitant/palonosetron/dexamethasone was superior to aprepitant/ondansetron/dexamethasone.Protracted administration of dexamethasone provided limited additional benefit. | Winnie Yeo Leung Li Thomas KH Lau Kwai T Lai Vicky,TC Chan Kwan H Wong Christopher CH Yip Elizabeth Pang Maggie Cheung Vivian Chan Carol CH Kwok Joyce JS Suen Frankie KF Mo | 2021 | Cancer Biology & Medicine2021，18，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员